esophageal candidiasis


Also found in: Wikipedia.

esophageal candidiasis

Candida esophagitis Infectious disease Inflammation by Candida spp Risk factors Immunocompromise–eg, AIDS, heart, kidney, other transplants, leukemia, lymphoma, chemotherapy Clinical Dysphagia; fever if systemic. See Candidiasis.
References in periodicals archive ?
Major exclusion criteria include previous ART or interleukin 2 therapy; diagnosis of an AIDS disease (including esophageal candidiasis and chronic Herpes simplex infection); other indicators of HIV progression such as oral thrush, unexplained weight loss or unexplained fever; myocardial infarction or another cardiovascular event within 6 months of randomization; non-AIDS cancer within 6 months of randomization; dialysis within 6 months of randomization; history of decompensated liver disease; current imprisonment or compulsory detention for psychiatric or physical illness; and current pregnancy or breastfeeding.
Approved in 2005 for the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation, MYCAMINE[R] was previously only available in a 50mg vial.
Micafungin, a member of the class known as echinocandins, was approved in the United States in 2005 for esophageal candidiasis and prophylactic treatment of bone marrow transplant patients.
The presence of oral thrush in a dysphagic HIV patient is an important physical examination finding which can help diagnose esophageal candidiasis.
Pfizer has also received FDA approval to treat two additional infections caused by the Candida fungus - peritonitis and intra-abdominal abscesses - as well as esophageal candidiasis, a fungal infection of the esophagus.
Esophageal candidiasis is a fungal infection of the esophagus that is most
Transnasal esophagoscopy detected florid esophageal candidiasis that involved the entire esophagus down to the gastroesophageal junction (figure).
Ally and colleagues conducted a randomized, double-blind, double-dummy, multicenter trial comparing the efficacy of voriconazole with that of fluconazole for the treatment of esophageal candidiasis in immunocompromised patients (29).
Upper endoscopy revealed only esophageal candidiasis, which was confirmed histologically.
Approved January 29, 1990 for the treatment of oropharyngeal and esophageal candidiasis and for the treatment of cryptococcal meningitis.
A randomized cross-over clinical and endoscopic evaluation of 85 Ugandan patients showed that esophageal candidiasis in AIDS patients with oral candidiasis could be managed without endoscopy and biopsies.
In some studies, women have had higher rates of esophageal candidiasis (yeast infections of the windpipe) and herpes simplex infections than men.

Full browser ?